<DOC>
	<DOCNO>NCT00965419</DOCNO>
	<brief_summary>The primary purpose child 's participation study determine whether LY2216684 help pediatric patient ADHD , assess safety LY2216684 side effect might associate .</brief_summary>
	<brief_title>A Study Pediatric Patients With Attention Deficit/Hyperactivity Disorder</brief_title>
	<detailed_description>12 week dose titration response assessment period . One ( 1 ) year open label treatment responder . Long-term extension 4 additional year responder .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Phenylethyl Alcohol</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients must meet Diagnostic &amp; Statistical Manual Mental Disorders 4th Ed diagnostic criterion ADHD base Kiddie Schedule Affective Disorders &amp; Schizophrenia School Aged Children Present Lifetime Version screen new patients/rollover patient . Patients must ADHDRSIVParent : Inv total score least 1.5 standard deviation age/gender norm screening/randomization . New patient must CGIADHDS score great equal 4 screening/randomization . Patients childbearing potential agree use reliable method birth control study 1 month follow last dose study drug . Female patient childbearing potential must test negative pregnancy time enrollment base urine pregnancy test . Patients must laboratory result , show clinically significant abnormality . Parents/patients must degree understanding sufficient communicate suitably investigator/ study coordinator . Patients must normal intelligence . Patients/parents must judge investigator reliable keep appointment clinic visits/all test , include venipuncture examination require protocol . Patients must able swallow tablet . EXCLUSION CRITERIA : Patients weigh less 16 kg screening/randomization . Female patient pregnant/breastfeeding . Patients previously withdrawn/discontinued early study study investigate LY2216684 . Patients history Bipolar I/II disorder , psychosis , pervasive developmental disorder . Patients history seizure disorder know electroencephalographic ( EEG ) abnormalities absence seizure . Patients serious suicidal risk . Patients history severe allergies 1 class medication , multiple adverse drug reaction , know hypersensitivity LY2216684 . Patients history alcohol drug abuse/dependence within past 3 month screen , currently use alcohol , drug abuse , prescribed overthecounter medication manner investigator considers indicative abuse/dependence . Patients screen positive drug abuse participate . Patients medical condition would increase sympathetic nervous system activity markedly , take medication daily basis sympathomimetic activity exclude . Patients problem would exacerbate increased norepinephrine tone include history cardiovascular disease , thyroid dysfunction , glaucoma , urinary retention . Patients time study likely need psychotropic medication apart drug study . Patients used monoamine oxidase inhibitor ( MAOI ) 2 week prior randomization . Patients current past history clinically significant hypertension . Patients currently enrol , discontinue within last 30 day clinical trial involve offlabel use investigational drug , concurrently enrol type medical research judge scientifically medically compatible study . Patients whose family anticipate move outside geographic range investigative site participation study plan extend travel inconsistent recommend visit interval . Patients , opinion investigator , unsuitable way participate study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>